Skip to main content
. 2022 Oct 27;14(21):5294. doi: 10.3390/cancers14215294

Figure 2.

Figure 2

(a) Expression of hepcidin in colorectal cancer samples (n = 256) and normal tissue samples (n = 41), as evaluated by using the UALCAN database (cancer vs. normal (**** p < 0.0001). (b–e) Expression of hepcidin RNA in different groups of CRC based on patients’ gender (b) [Normal (n = 41) versus CRC male (n = 156), **** p < 0.0001; Normal (n = 41) versus CRC female (n = 127), **** p < 0.0001], patients’ ethnicity (c) [Normal (n = 41) versus CRC Caucasian (n = 193), **** p < 0.0001; Normal (n = 41) versus CRC African American (n = 55), ** p < 0.01; Normal (n = 41) versus CRC Asian (n = 10), ns]; patients’ age (d), [Normal (n = 41) versus CRC 21–40 years (n = 12), * p < 0.05; Normal (n = 41) versus CRC 41–60 years (n = 90), *** p < 0.001; Normal (n = 41) versus CRC 61–80 years (n = 149), **** p < 0.0001; Normal (n = 41) versus CRC 81–100 years (n= 32), ** p < 0.01], patients’ weight [Normal (n = 41) versus CRC normal weight (n = 70), **** p < 0.0001; Normal (n = 41) versus CRC extreme weight (n = 74), **** p < 0.0001; Normal (n = 41) versus CRC obese (n = 56), *** p < 0.001; Normal (n = 41) versus CRC extreme obese (n= 10), ns] was examined by using the UALCAN database.